PERTH, Australia – Australian biotech company Patrys Ltd. is developing an antibody that can enter the cell nucleus. If clinical trials go well, it would be a game-changer, because it would mean that intracellular targets could be accessible to antibodies.
PERTH, Australia – Australia's Viralytics Ltd. is on its way to completing its phase Ib immunotherapy programs of lead candidate Cavatak following a A$29.6 million (US$23.9 million) private placement earlier this month with China's Lepu Medical Group.
PERTH, Australia – Most multinational pharma companies vehemently opposed the Therapeutic Goods Administration's plan to stick with the status quo in Australia and use a single name for biologics and biosimilars without a specific identifier suffix. Even so, the regulator said it would continue to use its single naming system and beef up its adverse event reporting system.
PERTH, Australia – Most multinational pharma companies vehemently opposed the Therapeutic Goods Administration's plan to stick with the status quo in Australia and use a single name for biologics and biosimilars without a specific identifier suffix. Even so, the regulator said it would continue to use its single naming system and beef up its adverse event reporting system.
PERTH, Australia – Australia’s Viralytics Ltd. is on its way to completing its phase Ib immunotherapy programs of lead candidate Cavatak following a A$29.6 million (US$23.9 million) private placement earlier this month with China’s Lepu Medical Group.
PERTH, Australia – Australia's Imugene Ltd. could be the first biotech out of the gate in developing B-cell peptide vaccines in the immune-oncology space.
PERTH, Australia – Australia's Imugene Ltd. could be the first biotech out of the gate in developing B-cell peptide vaccines in the immune-oncology space.
PERTH, Australia – A Senate inquiry on research funding models for cancers with low survival rates has returned a report that outlines 25 recommendations to improve infrastructure, clinical trials and reimbursement processes for cancer drugs in Australia.
